<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[alzheimer's disease Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/alzheimer%27s+disease.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to alzheimer's disease]]></description>
	<s:counts start="0" returned="20" found="147" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Suit: Lilly Touted Zyprexa for Alzheimer's Knowing It Was Ineffective; Sales Reps Had $10K Off-Label Promo Budgets]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002666/suit-lilly-touted-zyprexa-for-alzheimers-knowing-it-was-ineffective-sales-reps-had-10k-off-label-promo-budgets/]]></link>
		<description><![CDATA[Eli Lilly knew in 1995 that Zyprexa was ineffective for treating Alzheimer's and dementia in the elderly but promoted it for that purpose anyway, according to a lawsuit. The suit also claims that each Zyprexa sales rep had a $10,000 budget that it used to pay pharmacies and doctors for...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 12 Jun 2009 09:10:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Elan Sees Problems on Alzheimer's Drug; Puts Itself Up for Sale]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000597/elan-sees-problems-on-alzheimers-drug-puts-itself-up-for-sale/]]></link>
		<description><![CDATA[Elan, the troubled Irish pharma company, has put itself up for sale just as it emerged that it will spend another six months testing bapineuzumab, its experimental Alzheimer's treatment. The drug has previously been linked to brain swelling in some patients. The sale raises the possibility that Elan's bizarre managers...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 14 Jan 2009 06:02:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/bapineuzumab.html"><![CDATA[Bapineuzumab]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Will TorreyPines Sale of Its Alzheimer Genetics Research Save the Company?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F105365-will-torreypines-sale-of-its-alzheimer-genetics-research-save-the-company%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: TorreyPines Therapeutics, Inc. TPTX Tuesday announced that it has agreed to sell its Alzheimer&#8217;s disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 11 Nov 2008 07:58:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/torreypines+stock.html"><![CDATA[TorreyPines Stock]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/torreypines+therapeutics+inc..html"><![CDATA[TorreyPines Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">TPTX</category>
		<category domain="tickers">TPTX</category>
	</item>
	<item>
		<title><![CDATA[Glaxo and AFFiRiS Sign Alzheimer?s Disease Vaccine Deal]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F102991-glaxo-and-affiris-sign-alzheimers-disease-vaccine-deal%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits: GlaxoSmithKline Biologicals GSK and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS&#8217;s Alzheimer&#8217;s disease vaccine programs, aimed at treating Alzheimer&#8217;s by targeting beta-amyloid.  As part of the agreement, GSK is acquiring exclusive rights to develop and commercialize two Alzheimer&#8217;s...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 30 Oct 2008 08:19:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/affiris+affitope.html"><![CDATA[AFFiRiS AFFiTOPE]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000148/wyeth-elan-and-bapineuzumab-the-folly-of-subgroup-analysis/]]></link>
		<description><![CDATA[In what is becoming a sadly common ritual, Wyeth and Elan are pressing forward with an expensive, large-scale "phase III" trial of a risky drug based on wishful thinking and shoddy statistical analysis.    The drug in question is bapineuzumab, a monoclonal antibody intended to treat Alzheimer's disease...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 29 Jul 2008 14:15:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[How to Lose $100 Million in 40 Days]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000109/how-to-lose-100-million-in-40-days/]]></link>
		<description><![CDATA[The failure of Myriad Genetics' experimental Alzheimer's drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 01 Jul 2008 12:30:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/flurizan.html"><![CDATA[Flurizan]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[Phase I Data from Avid Radiopharmaceuticals' Alzheimer's and Parkinson's Disease Imaging Programs to be Presented at the 55th Annual Society of Nuclear Medicine Meeting]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_12/ai_n26671686]]></link>
		<description><![CDATA[Presentations Highlight Proof of Concept Results for Avid's Novel Molecular Imaging Agents]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 12 Jun 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/avid+technology+inc..html"><![CDATA[Avid Technology Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/imaging.html"><![CDATA[imaging]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AVID</category>
		<category domain="tickers">AVID</category>
	</item>
	<item>
		<title><![CDATA[MetLife Foundation Announces Major Awards to Scientists for Research in Alzheimer's Disease]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_29/ai_n24356991]]></link>
		<description><![CDATA[WASHINGTON -- Note to media: To listen in on the research briefing and hear this year's honorees discuss their work, as well as share thoughts on the future of research on Alzheimer's disease, a teleconference dial-in has been arranged: 800-230-1096. The briefing will take place between the hours of 10:30...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 29 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/metlife+inc..html"><![CDATA[MetLife Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MET</category>
		<category domain="tickers">MET</category>
	</item>
	<item>
		<title><![CDATA[Alzheimer's Foundation of America Attains BBB Seal for Charity Accountability]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5554/is_200802/ai_n25306956]]></link>
		<description><![CDATA[To: NATIONAL EDITORS To: NATIONAL EDITORS ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 11 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/accountability.html"><![CDATA[accountability]]></category>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Government of Canada Announces a $60,000 Contribution to the Alzheimer Society of Canada.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200801/ai_n22584756]]></link>
		<description><![CDATA[OTTAWA, ONTARIO, Jan 30, 2008 Marketwire via COMTEX --  Parliamentary Secretary Steven Fletcher, on behalf of the Honourable  Tony Clement, Minister of Health, today participated in a reception on  Parliament Hill marking the conclusion of Alzheimer's  OTTAWA, ONTARIO, Jan 30, 2008 Marketwire via COMTEX -- ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 30 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/government+of+canada.html"><![CDATA[Government of Canada]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab  in Alzheimer's Disease]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_21/ai_n21168262]]></link>
		<description><![CDATA[DUBLIN, Ireland & COLLEGEVILLE, Pa. -- Elan Corporation, plc (NYSE: ELN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the first patient in North America NA has been dosed as part of a global Phase 3 clinical program for bapineuzumab (AAB-001) in patients with mild to...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 21 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Alzheimer&#39;s Foundation of America Partners With AGIS for New Online Resource to Help Millions of Americans Caring for Loved Ones With Alzheimer&#39;s Disease and Dementia]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200712/ai_n21161590]]></link>
		<description><![CDATA[As the foremost online resource for family caregivers, AGIS is proud to announce their new Alzheimer's and Dementia caregivers section, created in partnership with the Alzheimer's Foundation of America AFA. AGIS' new free resource provides comprehensive online support for individuals caring for loved ones with Alzheimer's disease and dementia. ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 20 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Applied NeuroSolutions' Founding Scientist, Dr. Peter Davies, to Participate on an Expert Panel on Alzheimer's Disease Hosted by Credit Suisse]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_12/ai_n27473545]]></link>
		<description><![CDATA[VERNON HILLS, Ill. -- Applied NeuroSolutions, Inc. (OTC BB:APNS) (www.appliedneurosolutions.com), a Company focused on the development of an integrated portfolio of products for the treatment and diagnosis of Alzheimer's disease AD, today announced Dr. Peter Davies, its founding scientist, and the Judith and Burton P. Resnick Professor of Alzheimer's Disease...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/credit+suisse+group+ag.html"><![CDATA[Credit Suisse Group AG]]></category>
	</item>
	<item>
		<title><![CDATA[Frost & Sullivan Lauds Avid Radiopharmaceuticals For its Molecular Imaging Technology That Can Enable Early Diagnosis of Alzheimer's Disease]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_6/ai_n27467431]]></link>
		<description><![CDATA[PALO ALTO, Calif. -- Frost & Sullivan is proud to present Avid Radiopharmaceuticals, Inc. with the 2007 North American Molecular Imaging Technology Innovation of the Year Award for its pioneering contributions to the molecular imaging industry.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 06 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/avid+technology+inc..html"><![CDATA[Avid Technology Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/frost+%2526+sullivan.html"><![CDATA[Frost & Sullivan]]></category>
		<category domain="http://resources.bnet.com/topic/molecular+inc..html"><![CDATA[Molecular Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AVID</category>
		<category domain="tickers">AVID</category>
	</item>
	<item>
		<title><![CDATA[Biogen Idec and Neurimmune Therapeutics Announce Alliance to Develop Treatments for Alzheimer's Disease]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Nov_20/ai_n27450997]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. & ZURICH, Switzerland -- Biogen Idec (NASDAQ: BIIB) and Neurimmune Therapeutics AG today announced they have entered into an agreement for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer's disease AD. The alliance will focus on the development of antibodies that...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/alliance.html"><![CDATA[alliance]]></category>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Pipex Pharmaceuticals to Host Webcast to Discuss Results of Elevated Levels of Free Copper in Alzheimer's Disease and Third Quarter 2007 Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200711/ai_n21098222]]></link>
		<description><![CDATA[Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today its results and achievements for the three and nine month periods ended September 30, 2007.  Pipex will also hold a conference call on Thursday, November...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/webcast.html"><![CDATA[Webcast]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Evercare Unveils Details of Nation's First Alzheimer's Disease Special Needs Plan in Phoenix]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Oct_25/ai_n24352162]]></link>
		<description><![CDATA[Plan Couples Innovative Care Model with Banner Alzheimer's Institute's Specialized Services to Deliver Tailored Services for People with Alzheimer's and Related Dementia]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/phoenix+technologies.html"><![CDATA[Phoenix Technologies]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PTEC</category>
		<category domain="tickers">PTEC</category>
	</item>
	<item>
		<title><![CDATA[SanDisk Takes Action against Alzheimer's Disease with Special SanDisk Ultra II SD Card and Cruzer Micro USB Flash Drive]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_12/ai_n27370995]]></link>
		<description><![CDATA[SanDisk Will Contribute $1 To The Alzheimer's Association for Each Specially-Branded Product Purchased, Up To $1 Million]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 12 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/sandisk+corp..html"><![CDATA[SanDisk Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/sd+card.html"><![CDATA[SD card]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SNDK</category>
		<category domain="tickers">SNDK</category>
	</item>
	<item>
		<title><![CDATA[Applied NeuroSolutions Provides Update on Alzheimer's Disease Therapeutic Collaboration with Eli Lilly and Company]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_August_8/ai_n27336615]]></link>
		<description><![CDATA[Included in updated Corporate Presentation on company website]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 08 Aug 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="tickers">LLY</category>
	</item>
	<item>
		<title><![CDATA[Targacept Announces Initiation of Phase IIb Development of AZD3480  for Alzheimer's Disease]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_23/ai_n19378453]]></link>
		<description><![CDATA[WINSTON-SALEM, N.C. -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics[TM], today announced that its strategic collaborator AstraZeneca has initiated a Phase IIb clinical trial of AZD3480 (TC-1734) in Alzheimer's disease. AZD3480, Targacept's lead product candidate, acts selectively on neuronal...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 23 Jul 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's disease]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
